519 related articles for article (PubMed ID: 17953471)
1. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
4. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
Moses R
Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
6. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Nattrass M; Lauritzen T
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
[TBL] [Abstract][Full Text] [Related]
7. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag A
Diabetes Obes Metab; 2007 May; 9(3):394-407. PubMed ID: 17391168
[TBL] [Abstract][Full Text] [Related]
8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
Owens DR
Eur J Clin Invest; 1999 Jun; 29 Suppl 2():30-7. PubMed ID: 10383608
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide.
Balfour JA; Faulds D
Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.
Guay DR
Pharmacotherapy; 1998; 18(6):1195-204. PubMed ID: 9855316
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
15. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Wolffenbuttel BH; Landgraf R
Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
[TBL] [Abstract][Full Text] [Related]
16. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
Rutten GE
Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
18. Meglitinide analogues for type 2 diabetes mellitus.
Black C; Donnelly P; McIntyre L; Royle PL; Shepherd JP; Thomas S
Cochrane Database Syst Rev; 2007 Apr; 2007(2):CD004654. PubMed ID: 17443551
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]